| Take this short true or false quiz about treating related symptoms. |
|
|
|
 |
| NovoSeven® RT is used to treat bleeding episodes in people with hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with resistance to platelets, and acquired hemophilia. |
|
|
|
| You’re the expert on life with Glanzmann’s thrombasthenia. |
| This short quiz may offer new insight on treating symptoms related to Glanzmann’s thrombasthenia (GT). Start the quiz below. |
|
| Scroll to learn more about NovoSeven® RT. |
 |
|
| Selected Important Safety Information |
| What is the most important information I should know about NovoSeven® RT? |
| NovoSeven® RT may cause serious side effects, including: |
| • |
Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported |
|
| • |
Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function |
|
| • |
Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
| Features of NovoSeven® RT. |
|
If platelets don't work for you, NovoSeven® RT may be right for treating your GT-related bleeds. |
|
|
|
| What is NovoSeven® RT? |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: |
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions |
|
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia |
|
| Important Safety Information (cont’d) |
| • |
You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness |
|
| What should I tell my healthcare provider before using NovoSeven® RT? |
| • |
Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots: |
| |
| ◦ |
congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates) |
| ◦ |
are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding |
| ◦ |
history of heart or blood vessel diseases |
|
| • |
Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies |
|
| What are the possible side effects of NovoSeven® RT? |
| • |
The most common and serious side effects are blood clots |
|
| • |
Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction |
|
| Please click here for Prescribing Information. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| PLEASE DO NOT RESPOND TO THIS EMAIL. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
|
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US19NSVN00138 September 2020 |
 |
|
|
|